组蛋白去乙酰化酶抑制诱导儿童胶质瘤中促进肿瘤进展的关键支架蛋白表达:聚焦EBP50与IRSp53
研究探讨组蛋白去乙酰化酶抑制剂帕比司他(PS)对儿童弥漫性中线胶质瘤(DMG)细胞中支架蛋白EBP50和IRSp53的调控。BH3谱分析显示PS诱导胶质瘤细胞不可逆凋亡,蛋白质组学发现PS上调EBP50和IRSp53;沉默这些蛋白可抑制增殖、迁移、侵袭并增加凋亡。PS联合EBP50抑制在体外和鸡胚DMG模型中更有效减少细胞生长。
要点
- PS处理上调DMG细胞中支架蛋白EBP50和IRSp53。
- 沉默EBP50或IRSp53可阻断DMG细胞增殖、迁移、侵袭并增加凋亡。
- PS联合EBP50抑制在体外和鸡胚模型中更有效减少胶质瘤细胞生长。
核心结论
- 数据揭示HDAC抑制剂与支架蛋白失调之间的特定关系,可能具有癌症治疗干预的潜力。
研究设计与样本
- 使用3个DMG细胞系进行蛋白质组学分析,并通过BH3谱分析、膜联蛋白V/碘化丙啶染色、沉默RNA、体外实验及鸡胚DMG模型研究PS效应。
主要发现
- BH3谱分析显示PS暴露的胶质瘤细胞进入不可逆凋亡过程,经膜联蛋白V/碘化丙啶染色确认。
- 蛋白质组学分析发现PS处理后EBP50和IRSp53上调。
- 降低DMG细胞系中这些蛋白导致增殖、迁移和侵袭受阻,凋亡增加。
- EBP50在DMG细胞的细胞质和细胞核中表达,确认其已知的致癌定位。
- PS联合EBP50的遗传或化学抑制在体外和体内更有效减少细胞生长。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors such as panobinostat (PS) is therefore a novel therapeutic option currently evaluated in clinical trials. METHODS: BH3 profiling revealed engagement in an irreversible apoptotic process of glioma cells exposed to PS confirmed by annexin-V/propidium iodide staining. Using proteomic analysis of 3 DMG cell lines, we identified 2 proteins deregulated after PS treatment. We investigated biological effects of their downregulation by silencing RNA but also combinatory effects with PS treatment in vitro and in vivo using a chick embryo DMG model. Electron microscopy was used to validate protein localization. RESULTS: Scaffolding proteins EBP50 and IRSp53 were upregulated by PS treatment. Reduction of these proteins in DMG cell lines leads to blockade of proliferation and migration, invasion, and an increase of apoptosis. EBP50 was found to be expressed in cytoplasm and nucleus in DMG cells, confirming known oncogenic locations of the protein. Treatment of glioma cells with PS together with genetic or chemical inhibition of EBP50 leads to more effective reduction of cell growth in vitro and in vivo. CONCLUSION: Our data reveal a specific relation between HDAC inhibitors and scaffolding protein deregulation which might have a potential for therapeutic intervention for cancer treatment.
引用
- Capdevielle C, Desplat A, Charpentier J, et al. HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53. Neuro Oncol. 2020. PMID: 31711240. doi:10.1093/neuonc/noz215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。